A phase I study of the safety, tolerability and antitumor activity of escalating doses of combretastatin A4 phosphate (CA4P) given in combination with bevacizumab to subjects with advanced solid tumors
Những tác giả chính: | Nathan, P, Judson, I, Padhani, A, Harris, A, Sinha, R, Jane, B, Smythe, J, Fisher, N, Taylor, J, Collins, D, Connors, H, Gordon, R |
---|---|
Định dạng: | Journal article |
Được phát hành: |
2007
|
Những quyển sách tương tự
-
A phase I study of combretastatin A4 phosphate (CA4P) and bevacizumab in subjects with advanced solid tumors
Bằng: Nathan, P, et al.
Được phát hành: (2008) -
Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer.
Bằng: Nathan, P, et al.
Được phát hành: (2012) -
Vascular effects dominate solid tumor response to treatment with combretastatin A-4-phosphate
Bằng: Jane Lunt, S, et al.
Được phát hành: (2011) -
The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses.
Bằng: Prise, V, et al.
Được phát hành: (2002) -
Vascular effects dominate solid tumor response to treatment with combretastatin A-4-phosphate.
Bằng: Lunt, S, et al.
Được phát hành: (2011)